News
ATOS
--
0.00%
--
BRIEF-Atos And Johnson Controls Announce Global Partnership
reuters.com · 17h ago
Atossa Therapeutics Shares See Volume; Traders Circulate SeekingAlpha Article 'Atossa Therapeutics Is A Takeover Target Worth Triple It's Current Stock Price.'
https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5640574-atossa-therapeutics-is-takeover-target-worth-triple-current-stock-price
Benzinga · 3d ago
'3 Reasons to Love Atossa Therapeutics Stock' -TipRanks
https://www.tipranks.com/news/article/3-reasons-to-love-atossa-therapeutics-stock/
Benzinga · 09/10 17:50
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden
Benzinga · 09/02 15:00
Atossa Therapeutics Reports Approval From Swedish Ethics Review Authority To Initiate Phase 2 Study Of Oral Endoxifen To Reduce Mammographic Breast Density
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with
Benzinga · 09/02 13:31
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious disea...
GlobeNewswire · 09/02 13:30
Sabby Management, Llc Buys Cocrystal Pharma Inc, Enochian BioSciences Inc, Aterian Inc, Sells ...
GuruFocus News · 08/18 14:38
Atossa Genetics Shares Spike Higher On Volume, Now Up 3%; Traders Circulate TipRanks Article 'Atossa: Strong Balance Sheet Will Support the Pipeline's Advance, Says Analyst'
https://blog.tipranks.com/atossa-strong-balance-sheet-will-support-the-pipelines-advance-says-analyst/
Benzinga · 08/17 17:11
BRIEF-Atossa Therapeutics Reports Qtrly Loss Per Share $0.06
reuters.com · 08/13 13:58
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious disea...
GlobeNewswire · 08/05 13:30
Analyzing Atossa Therapeutics's Unusual Options Activity
Atossa Therapeutics (NASDAQ:ATOS) shares experienced unusual options activity on Wednesday. The stock price moved up to $3.29 following the option alert.
Benzinga · 08/04 15:38
63 Biggest Movers From Yesterday
Gainers
Benzinga · 08/02 09:12
Flora Growth leads weekly healthcare gainers; Alzheimer’s-focused stocks trail
After four back-to-back sessions of gains, the healthcare stocks in the S&P 500 finished ~0.5% higher this week to outperform the ~0.4% loss recorded by the broader index over the past five-day period. A
Seekingalpha · 07/31 20:40
ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today
Investor Place · 07/30 19:04
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers
Benzinga · 07/30 17:14
MRIN, BLIN, BAP among mid-day movers
Gainers: ERYTECH Pharma ERYP +64%. Allied Healthcare Products AHPI +49%. iFresh (NASDAQ:IFMK) +35%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Atlassian Corporation TEAM +24%. Xiaobai Maimai (NASDAQ:HX) +18%. First High-School Education (NYSE:FHS) +16...
Seekingalpha · 07/30 16:36
Atossa Therapeutics Seeks Shareholder Approval to Expand Authorized Common Shares -- Shares Plunge
MT Newswires · 07/30 15:27
ERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losers
Gainers: ERYTECH Pharma (NASDAQ:ERYP) +84%, Allied Healthcare Products (NASDAQ:AHPI) +31%, SCWorx (NASDAQ:WORX) +18%, Veracyte (NASDAQ:VCYT) +13%, Misonix (NASDAQ:MSON) +11%. Losers: Intec Pharma (NASDAQ:NTEC) -20%, Translate Bio (NASDAQ:TBIO) -17%, ATI Ph...
Seekingalpha · 07/30 15:00
Atossa loses a tenth after convening a special meeting for shareholders
Atossa Therapeutics (ATOS -13.2%) has lost more than a tenth in value in morning hours after the company announced a special meeting of stockholders seeking approval for an amendment to the
Seekingalpha · 07/30 13:51
Understanding Atossa Therapeutics's Unusual Options Activity
Atossa Therapeutics (NASDAQ:ATOS) shares experienced unusual options activity on Thursday. The stock price moved up to $4.08 following the option alert.
Benzinga · 07/29 16:30
Webull provides a variety of real-time ATOS stock news. You can receive the latest news about Atossa Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATOS
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. It is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.